Larger group testing
The next step is to carry out longer testing of the treatment in much larger groups of people (sometimes thousands) with the specific condition, compared against an existing treatment or a placebo to see which works better, while still checking side effects.
If you are interested in any of these studies, please talk to your Respiratory Team.
Interstitial lung diseases
- TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial:
- The cause of idiopathic pulmonary fibrosis (IPF) is unknown, but there’s evidence suggesting that regular intake of anti-acid drugs like lansoprazole might slow its progression. These drugs reduce stomach acid, believed by some scientists to contribute to lung scarring. The TIPAL Study explores if adding lansoprazole slows lung function decline in IPF, assessing its impact on symptoms and quality of life compared to existing treatments. Click here for more info. CURRENTLY RECRUITING.
- FIBRONEER-SARD: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with systemic autoimmune rheumatic diseases associated interstitial lung diseases (SARD-ILD):
- Further characterising the efficacy and safety profile of nerandomilast on top of a broad range of immunosuppressants has been identified as an important unmet need. Understanding the potential risk of infections is a focus and is informative for the safety profile in association with this potential therapy in patients commonly seen by rheumatologists. Visit here for more information. CURRENTLY RECRUITING.
- CHORUS: A multi-centre double-blind randomised placebo-controlled group-sequential superiority trial to assess the effectiveness and cost-effectiveness of oral Corticosteroids in patients witH fibrOtic hypeRsensitivity pneUmonitiS:
- A UK non-commercial NIHR study assessing the effectiveness of treatment with prednisolone versus placebo on progression of lung function.
- Zephyrus II: A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis:
- The purpose of this study is to test whether Pamrevlumab will slow down the progression of IPF. Pamrevlumab works by interfering with neutralising Connective Tissue Growth Factor (CTGF), a protein that the body normally produces. Studies have shown increased activity/levels of CTGF in IPF patients, which might be an important factor in the disease progression. Recruitment has now closed. For further background reading on Pamrevlumab, click here.
See how your donations have contributed to our ground-breaking research
2025 ILD Research Report
Sign up!
Receive our latest research updates and news